These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 24620922)

  • 1. The fibroblast growth factor-23 and Vitamin D emerge as nontraditional risk factors and may affect cardiovascular risk.
    Masson S; Agabiti N; Vago T; Miceli M; Mayer F; Letizia T; Wienhues-Thelen U; Mureddu GF; Davoli M; Boccanelli A; Latini R;
    J Intern Med; 2015 Mar; 277(3):318-330. PubMed ID: 24620922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation.
    Seiler S; Cremers B; Rebling NM; Hornof F; Jeken J; Kersting S; Steimle C; Ege P; Fehrenz M; Rogacev KS; Scheller B; Böhm M; Fliser D; Heine GH
    Eur Heart J; 2011 Nov; 32(21):2688-96. PubMed ID: 21733911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitamin D metabolites and fibroblast growth factor-23 in patients with left ventricular assist device implants: association with stroke and mortality risk.
    Zittermann A; Morshuis M; Kuhn J; Pilz S; Ernst JB; Oezpeker C; Dreier J; Knabbe C; Gummert JF; Milting H
    Eur J Nutr; 2016 Feb; 55(1):305-13. PubMed ID: 25657014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between hypervolemia, left ventricular hypertrophy and fibroblast growth factor 23 in hemodialysis patients.
    Unver S; Kavlak E; Gümüsel HK; Celikbilek F; Esertas K; Muftuoglu T; Kirilmaz A
    Ren Fail; 2015 Jul; 37(6):951-6. PubMed ID: 26030798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibroblast Growth Factor-23 and Frailty in Elderly Community-Dwelling Individuals: The Cardiovascular Health Study.
    Beben T; Ix JH; Shlipak MG; Sarnak MJ; Fried LF; Hoofnagle AN; Chonchol M; Kestenbaum BR; de Boer IH; Rifkin DE
    J Am Geriatr Soc; 2016 Feb; 64(2):270-6. PubMed ID: 26889836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.
    Gutiérrez OM; Januzzi JL; Isakova T; Laliberte K; Smith K; Collerone G; Sarwar A; Hoffmann U; Coglianese E; Christenson R; Wang TJ; deFilippi C; Wolf M
    Circulation; 2009 May; 119(19):2545-52. PubMed ID: 19414634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between fibroblast growth factor 23 and left ventricular hypertrophy in maintenance hemodialysis patients. Comparison with B-type natriuretic peptide and cardiac troponin T.
    Negishi K; Kobayashi M; Ochiai I; Yamazaki Y; Hasegawa H; Yamashita T; Shimizu T; Kasama S; Kurabayashi M
    Circ J; 2010 Nov; 74(12):2734-40. PubMed ID: 21041973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibroblast growth factor is associated to left ventricular mass index, anemia and low values of transferrin saturation.
    Eser B; Yayar O; Buyukbakkal M; Erdogan B; Ercan Z; Merhametsiz O; Haspulat A; Oğuz EG; Dogan İ; Canbakan B; Ayli MD
    Nefrologia; 2015; 35(5):465-72. PubMed ID: 26394828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibroblast growth factor 23 and left ventricular hypertrophy in children on dialysis.
    Seeherunvong W; Abitbol CL; Chandar J; Rusconi P; Zilleruelo GE; Freundlich M
    Pediatr Nephrol; 2012 Nov; 27(11):2129-2136. PubMed ID: 22710695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-sensitivity cardiac troponin T for detection of subtle abnormalities of cardiac phenotype in a general population of elderly individuals.
    Masson S; Latini R; Mureddu GF; Agabiti N; Miceli M; Cesaroni G; Forastiere F; Wienhues-Thelen UH; Block D; Zaugg C; Vago T; Boccanelli A;
    J Intern Med; 2013 Mar; 273(3):306-17. PubMed ID: 23216903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibroblast growth factor-23 helps explain the biphasic cardiovascular effects of vitamin D in chronic kidney disease.
    Hu P; Xuan Q; Hu B; Lu L; Wang J; Qin YH
    Int J Biol Sci; 2012; 8(5):663-71. PubMed ID: 22606047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PTH, vitamin D, and the FGF-23-klotho axis and heart: Going beyond the confines of nephrology.
    Navarro-García JA; Fernández-Velasco M; Delgado C; Delgado JF; Kuro-O M; Ruilope LM; Ruiz-Hurtado G
    Eur J Clin Invest; 2018 Apr; 48(4):. PubMed ID: 29394451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibroblast growth factor 23 and sudden versus non-sudden cardiac death: the Cardiovascular Health Study.
    Deo R; Katz R; de Boer IH; Sotoodehnia N; Kestenbaum B; Mukamal KJ; Chonchol M; Sarnak MJ; Siscovick D; Shlipak MG; Ix JH
    Am J Kidney Dis; 2015 Jul; 66(1):40-6. PubMed ID: 25572028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum fibroblast growth factor-23 (FGF-23) levels are independently associated with left ventricular mass and myocardial performance index in maintenance haemodialysis patients.
    Kirkpantur A; Balci M; Gurbuz OA; Afsar B; Canbakan B; Akdemir R; Ayli MD
    Nephrol Dial Transplant; 2011 Apr; 26(4):1346-54. PubMed ID: 20813767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast growth factor 23 (FGF23) and mortality: the Ludwigshafen Risk and Cardiovascular Health Study.
    Brandenburg VM; Kleber ME; Vervloet MG; Tomaschitz A; Pilz S; Stojakovic T; Delgado G; Grammer TB; Marx N; März W; Scharnagl H
    Atherosclerosis; 2014 Nov; 237(1):53-9. PubMed ID: 25200615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibroblast Growth Factor 23 Is an Independent and Specific Predictor of Mortality in Patients With Heart Failure and Reduced Ejection Fraction.
    Koller L; Kleber ME; Brandenburg VM; Goliasch G; Richter B; Sulzgruber P; Scharnagl H; Silbernagel G; Grammer TB; Delgado G; Tomaschitz A; Pilz S; Berger R; Mörtl D; Hülsmann M; Pacher R; März W; Niessner A
    Circ Heart Fail; 2015 Nov; 8(6):1059-67. PubMed ID: 26273098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibroblast growth factor 23 correlates with volume status in haemodialysis patients and is not reduced by haemodialysis.
    Humalda JK; Riphagen IJ; Assa S; Hummel YM; Westerhuis R; Vervloet MG; Voors AA; Navis G; Franssen CF; de Borst MH;
    Nephrol Dial Transplant; 2016 Sep; 31(9):1494-501. PubMed ID: 26602863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coexistence of low vitamin D and high fibroblast growth factor-23 plasma levels predicts an adverse outcome in patients with coronary artery disease.
    Tuñón J; Cristóbal C; Tarín N; Aceña Á; González-Casaus ML; Huelmos A; Alonso J; Lorenzo Ó; González-Parra E; Mahíllo-Fernández I; Pello AM; Carda R; Farré J; Rodríguez-Artalejo F; López-Bescós L; Egido J
    PLoS One; 2014; 9(4):e95402. PubMed ID: 24748388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
    Sprague SM; Wetmore JB; Gurevich K; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
    Clin J Am Soc Nephrol; 2015 Jun; 10(6):1021-30. PubMed ID: 25873267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population.
    Mirza MA; Larsson A; Melhus H; Lind L; Larsson TE
    Atherosclerosis; 2009 Dec; 207(2):546-51. PubMed ID: 19524924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.